tetano
Editor, Senior Moderator
Frontline Gastroenterol
. 2020 Aug 21;12(2):89-94.
doi: 10.1136/flgastro-2020-101532. eCollection 2021.
Incidence, pattern and severity of abnormal liver blood tests among hospitalised patients with SARS-COV2 (COVID-19) in South Wales
Andrew Yeoman[SUP] 1 [/SUP], Daniel Raun Maggs[SUP] 1 [/SUP], Syed A A Gardezi[SUP] 1 [/SUP], Hasan Nadim Haboubi[SUP] 1 [/SUP], Muhammad Imran Yahya[SUP] 1 [/SUP], Fidan Yousuf[SUP] 1 [/SUP], Marek Alexander Czajkowski[SUP] 1 [/SUP]
Affiliations
Abstract
Introduction: SARS-CoV-2 (COVID-19) is a novel coronavirus that emerged in Wuhan, China in late 2019 and since become a global pandemic. As such, its clinical behaviour is a subject of much interest. Initial reports suggested a significant proportion of patients have abnormal liver blood tests. Gwent has experienced one of the highest incidences of COVID-19 infection in the UK, which itself has among the highest COVID-19 impacts worldwide.
Method: We set out to report the incidence, clinical pattern and severity of liver blood test abnormalities in hospitalised patients with confirmed COVID-19 in our institution over a 3-week period. Data on clinical outcomes such as admission to intensive therapy unit (ITU), hospital discharge and mortality were recorded.
Results: 318 hospitalised COVID-19 positive had liver blood tests available for analysis. Ninety-seven patients (31%) had one or more abnormal liver blood tests and were abnormal admission in 64%. Liver tests were predominantly cholestatic (72%) in contrast to other studies to date. Male gender and abnormal liver blood tests were associated with ITU admission.
Conclusions: Almost one-third of admissions with COVID-19 have abnormal LBTs which are typically mild and are associated with male gender. Importantly, we have identified that cholestatic patterns dominate but were not clearly associated with ITU admission or death.
Keywords: cholestasis; hepatitis.
. 2020 Aug 21;12(2):89-94.
doi: 10.1136/flgastro-2020-101532. eCollection 2021.
Incidence, pattern and severity of abnormal liver blood tests among hospitalised patients with SARS-COV2 (COVID-19) in South Wales
Andrew Yeoman[SUP] 1 [/SUP], Daniel Raun Maggs[SUP] 1 [/SUP], Syed A A Gardezi[SUP] 1 [/SUP], Hasan Nadim Haboubi[SUP] 1 [/SUP], Muhammad Imran Yahya[SUP] 1 [/SUP], Fidan Yousuf[SUP] 1 [/SUP], Marek Alexander Czajkowski[SUP] 1 [/SUP]
Affiliations
- PMID: 33617606
- PMCID: PMC7873537
- DOI: 10.1136/flgastro-2020-101532
Abstract
Introduction: SARS-CoV-2 (COVID-19) is a novel coronavirus that emerged in Wuhan, China in late 2019 and since become a global pandemic. As such, its clinical behaviour is a subject of much interest. Initial reports suggested a significant proportion of patients have abnormal liver blood tests. Gwent has experienced one of the highest incidences of COVID-19 infection in the UK, which itself has among the highest COVID-19 impacts worldwide.
Method: We set out to report the incidence, clinical pattern and severity of liver blood test abnormalities in hospitalised patients with confirmed COVID-19 in our institution over a 3-week period. Data on clinical outcomes such as admission to intensive therapy unit (ITU), hospital discharge and mortality were recorded.
Results: 318 hospitalised COVID-19 positive had liver blood tests available for analysis. Ninety-seven patients (31%) had one or more abnormal liver blood tests and were abnormal admission in 64%. Liver tests were predominantly cholestatic (72%) in contrast to other studies to date. Male gender and abnormal liver blood tests were associated with ITU admission.
Conclusions: Almost one-third of admissions with COVID-19 have abnormal LBTs which are typically mild and are associated with male gender. Importantly, we have identified that cholestatic patterns dominate but were not clearly associated with ITU admission or death.
Keywords: cholestasis; hepatitis.